inupadenant

DRUG4 trials

Sponsors

iTeos Belgium, iTeos Belgium SA, iTeos Therapeutics

Conditions

Advanced CancerAdvanced solid tumorsHead and Neck CancerLocally Advanced NSCLC - Non-Small Cell Lung CancerLung CancerMelanomaMetastatic NSCLC - Non-Small Cell Lung CancerSolid Tumor, Adult

Phase 1

Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors

Active, not recruitingNCT05060432

iTeos Belgium SAAdvanced Cancer, Head and Neck Cancer, Lung Cancer +1

Start: 2021-09-06End: 2025-07-31Updated: 2024-06-21

New Formulation Study of Inupadenant (EOS100850) in Patients with Cancer

CompletedNCT05117177

iTeos TherapeuticsSolid Tumor, Adult

Start: 2021-07-01End: 2024-05-09Updated: 2024-09-19

A Multicenter, Open-Label, Phase I/II Study of EOS884448 in combination with standard of care and/or investigational therapies in participants with advanced solid tumors

CompletedCTIS2024-512227-36-00

iTeos BelgiumAdvanced solid tumors

Start: 2021-07-28End: 2025-05-15Target: 206Updated: 2025-05-06

Phase 2

Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

Active, not recruitingNCT05403385

iTeos TherapeuticsLocally Advanced NSCLC - Non-Small Cell Lung Cancer, Metastatic NSCLC - Non-Small Cell Lung Cancer

Start: 2022-08-26End: 2025-10-31Updated: 2025-08-03